NCT01646151已完成不适用
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 2,580
- 主要终点
- Intraocular Pressure (IOP) at Baseline
研究概览
简要总结
An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Visits and treatment are per normal clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of POAG or OHT
- •Previous use of IOP-lowering medication
排除标准
- 未提供
研究组 & 干预措施
Bimatoprost
Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
干预措施: Bimatoprost (Drug)
结局指标
主要结局
Intraocular Pressure (IOP) at Baseline
时间窗: Baseline
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eyes at Baseline.
IOP at Week 12
时间窗: Week 12
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eyes at Week 12.
次要结局
- Physician Evaluation of IOP Lowering in the Study Eye(s)(Week 12)
- Patient Assessment of Tolerability on a 4-Point Scale(Week 12)
- Physician Assessment of Tolerability on a 4-Point Scale(Week 12)
- Physician Assessment of Patient Compliance Compared to Previous Therapy(Week 12)
- Percentage of Patients Who Discontinue Treatment With Bimatoprost-Containing Eye Drops Prior to 12 Weeks of Treatment(12 Weeks)
- Percentage of Patients Who Continue Treatment With Bimatoprost-Containing Eye Drops(Week 12)
研究者
相似试验
已完成
不适用
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)Ocular HypertensionOpen-Angle GlaucomaNCT00716742Allergan1,099
已完成
4 期
Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular HypertensionGlaucomaNCT00348023Innovative Medical
已完成
4 期
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to LatanoprostGlaucomaNCT00347841Innovative Medical
Unknown
不适用
Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over StudyGlaucoma, Angle-ClosureNCT00567788Singapore National Eye Centre60
终止
3 期
Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPTGlaucomaOcular HypertensionNCT00767494Alcon Research17